During development, 17alpha-estradiol is a potent estrogen and carcinogen

Area of Science:

• Endocrinology
• Reproductive Toxicology
• Developmental Biology

Background:

• Neonatal exposure to estrogens like estradiol-17beta (E2-17beta) can induce lasting changes in the reproductive tract.
• Environmental estrogens raise concerns about similar effects, necessitating investigation into their potency.
• Estradiol-17alpha (E2-17alpha), a stereoisomer of E2-17beta, was examined for its potential to cause abnormal reproductive changes.

Purpose of the Study:

• To determine if neonatal administration of E2-17alpha causes abnormal changes in the mouse reproductive tract.
• To assess the tumorigenic potential of neonatal E2-17alpha exposure.
• To investigate whether the effects of E2-17alpha are age-dependent.

Main Methods:

• Female BALB/c mice received neonatal treatment (days 1-5) with E2-17beta, E2-17alpha, or cholesterol.
• A subset of mice received short-term secondary administration of E2-17beta, E2-17alpha, or cholesterol.
• Cervicovaginal tracts were analyzed histologically and by flow cytometry at 70 days and 18-22 months of age.

Main Results:

• Neonatal E2-17alpha induced persistent vaginal cornification, hypospadias, and hyperproliferation in nearly all animals.
• E2-17alpha increased cervicovaginal epithelial DNA content, though less than E2-17beta.
• Neonatal E2-17alpha administration led to adenosquamous tumors in 25% of the mice.

Conclusions:

• Neonatal E2-17alpha exhibits estrogenic activity and can induce reproductive abnormalities.
• E2-17alpha possesses tumorigenic potential in the mouse reproductive tract.
• The biological effects and potency of E2-17alpha may be age-dependent, warranting further research.